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The risk of hemorrhage from unruptured brain ar-teriovenous malformations (ubAVMs) is approxi-mately 2.2% per year.9 Even though a number of risk 
factors have been proposed that may modify this overall 
rate,2–4,8,10–12,21,22,27–30,33 an analysis of the literature shows 
that recent diagnosis, deep location, and associated aneu-
rysms may be associated with an increased risk of future 
hemorrhage.9 Presentation with hemorrhage is also a re-
ported risk factor3,4,7,8,10–12,21,28,31,33 but does not relate to our 
study looking at only ubAVMs. The cumulative risk of first 
hemorrhage over 20 years has been reported to be 29%.11
The consequence of a hemorrhage occurring in a di-
agnosed ubAVM while under surveillance is significant. 
Mortality of 6%–29%, permanent morbidity of 16%–
35%, and combined morbidity and mortality of 41%–85% 
have been reported.2–4,20
Surgery for unruptured arteriovenous malformations of the 
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Object. The aim of this study was to identify patients who are likely to benefit from surgery for unruptured brain 
arteriovenous malformations (ubAVMs).
Methods. The authors’ database was interrogated for the risk and outcome of hemorrhage after referral and the out-
come from surgery. Furthermore, the outcome from surgery incorporated those cases excluded from surgery because of 
perceived greater risk (sensitivity analysis). Finally, a comparison was made for the authors’ patients between the natural 
history and surgery. Data were collected for 427 consecutively enrolled patients with ubAVMs in a database that in-
cluded patients who were conservatively managed. Kaplan-Meier analysis was performed on patients observed for more 
than 1 day to determine the risk of hemorrhage. Variables that may influence the risk of first hemorrhage were assessed 
using Cox proportional hazard regression models and Kaplan-Meier life table analyses from referral until the first occur-
rence of the following: hemorrhage, treatment, or last review. The outcome from surgery (leading to a new permanent 
neurological deficit with last review modified Rankin Scale [mRS] score > 1) was determined. Further sensitivity analy-
sis was made to predict risk from surgery for the total ubAVM cohort by incorporating outcomes of surgical cases as well 
as cases excluded from surgery because of perceived risk, and assuming an adverse outcome for these excluded cases.
Results. A total of 377 patients with a ubAVM were included in the analysis of the risk of hemorrhage. The 
5-year risk of hemorrhage for ubAVM was 11.5%. Hemorrhage resulted in an mRS score > 1 in 14 cases (88% [95% 
CI 63%–98%]). Patients with Spetzler-Ponce Class A ubAVMs treated by surgery (n = 190) had a risk from surgery 
of 1.6% (95% CI 0.3%–4.8%) for a permanent neurological deficit leading to an mRS score > 1 and 0.5% (95% CI 
< 0.1%–3.2%) for a permanent neurological deficit leading to an mRS score > 2. Patients with Spetzler-Ponce Class 
B ubAVMs treated by surgery (n = 107) had a risk from surgery of 14.0% (95% CI 8.6%–22.0%) for a permanent 
neurological deficit leading to an mRS score > 1. Sensitivity analysis of Spetzler-Ponce Class B ubAVMs, including 
those in patients excluded from surgery, showed that the true risk for surgically eligible patients may have been as 
high as 15.6% (95% CI 9.9%–23.7%) for mRS score > 1, had all patients who were perceived to have a greater risk 
experienced an adverse outcome. Patients with Spetzler-Ponce Class C ubAVMs treated by surgery (n = 44) had a 
risk from surgery of 38.6% (95% CI 25.7%–53.4%) for a permanent neurological deficit leading to an mRS score > 
1. Sensitivity analysis of Class C ubAVMs, including those harbored by patients excluded from surgery, showed that 
the true risk for surgically eligible patients may have been as high as 60.9% (95% CI 49.2%–71.5%) for mRS score 
> 1, had all patients who were perceived to have a greater risk experienced an adverse outcome.
Conclusions. Surgical outcomes for Spetzler-Ponce Class A ubAVMs are better than those for conservative 
management.
(http://thejns.org/doi/abs/10.3171/2014.7.JNS132691)
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Cox regression      •      Kaplan-Meier      •      surgery      •      prospective cohort      •       
vascular disorders
Abbreviations used in this paper: ARUBA = A Randomized 
Trial of Unruptured Brain Arteriovenous Malformations; AVM = 
arteriovenous malformation; bAVM = brain AVM; DSA = digital 
subtraction angiography; mRS = modified Rankin Scale; RCT = 
randomized controlled trial; ubAVM = unruptured brain AVM.
See the corresponding editorial in this issue, pp 875–877.
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The risk from surgery for brain AVMs has been strati-
fied by the Spetzler-Martin grading system using 3 compo-
nents of the AVM: size, deep venous drainage, and eloquent 
location.5,13,23,25,26 The importance of this grading system is 
to assist in selection of cases with a low risk of permanent 
adverse outcomes from surgery. It has been recommended 
by Spetzler and Ponce that the grading system can best be 
reduced to 3 tiers: Spetzler-Martin Grades I and II (Spetz-
ler-Ponce Class A), Spetzler-Martin Grade III (Spetz ler-
Ponce Class B), and Spetzler-Martin Grades IV and V 
(Spetzler-Ponce Class C).26 This risk has been reported 
to be 8% in a combined series for Spetzler-Ponce Class A 
ubAVMs and no greater than 1% in 3 series.26 Some series 
reported the lack of impact of size or eloquent location of 
AVMs on surgical outcome.14,24 This may be explained by 
cohort surgical series that do not take into consideration 
patients at high risk because they have been excluded from 
surgical treatment. Davidson and Morgan attempted to ac-
count for the patients who had been excluded from surgi-
cal treatment and concluded that all the variables of the 
Spetzler-Martin grading system were of importance and 
that the Spetzler-Martin grading system was a reliable 
way of stratifying risks from surgery.5 The principle for 
this 3-tier grading is based upon series incorporating both 
ruptured and unruptured brain AVMs (bAVMs). The appli-
cation of the Spetzler-Martin grading system for risk from 
surgery is likely reasonable. However, no large series of 
ubAVMs report on the application of the Spetzler-Martin 
grading system in predicting surgical outcome to date. We 
showed that the risks reported for outcome for surgery for 
Spetzler-Ponce Class A ubAVMs could be generalized to 
all patients suitable for surgery with Spetzler-Ponce Class 
A ubAVMs (both operated and unoperated) due to the very 
high proportion of patients treated by surgery, whereas 
the surgical series results for Spetzler-Ponce Class B and 
Spetzler-Ponce Class C ubAVMs could not be generalized 
due to selection bias (that is, exclusion of high-risk cases in 
surgical series). This bias relates to patients excluded from 
surgery because of perceived surgical risk.5 If this number 
is a large percentage of the group as a whole, the surgical 
risk reported will underestimate the risks for all patients 
with similar Spetzler-Ponce class ubAVMs.
Because of the complexity of potential risks of first 
hemorrhage, the variability in outcomes of management, 
and the perceived absence of compelling data from case 
series, A Randomized Trial of Unruptured Brain Arterio-
venous Malformations (ARUBA) was undertaken. Within 
ARUBA, 7.9% (10 patients) of the medical management 
arm experienced death or stroke compared with 35% (34 
patients) of the interventional therapy arm over 33 months 
with a relative risk of 0.35 (95% CI 0.19–0.65).1 This 
study was performed to “compare the risk of death and 
symptomatic stroke in patients with an unruptured brain 
arteriovenous malformation who are allocated to either 
medical management alone or medical management with 
planned efforts at eradication of the brain arteriovenous 
malformation with interventional therapy.”17 This inter-
ventional therapy included some surgery for 16% (the sole 
modality in 4% of cases), radiotherapy (presumably fo-
cused irradiation) in 26%, and some contribution by em-
bolization in 40% (the sole modality in 26% of cases).17
Although ARUBA was initially aimed and powered 
to recruit 800 patients, the study was ultimately analyzed 
for a total of 223 patients from 39 centers. The difficulty 
of recruitment encountered with ARUBA is unlikely to 
be overcome with future randomized controlled trials 
(RCTs) due to the need for “ethical equipoise” and the in-
creasing knowledge of the natural history of ubAVMs, the 
low surgical risks for Spetzler-Ponce Class A ubAVMs, 
and the high surgical risks for Spetzler-Ponce Class C 
ubAVMs. Therefore, a role remains for large cohort series 
from prospectively collected databases (with enough in-
formation for the selection bias available to the reader) to 
provide evidence to answer the question, “Can treatment 
be superior to nontreatment for ubAVM?”
We performed an analysis of a prospectively collected 
database of ubAVMs for both the natural history of hem-
orrhage and the risk from surgery. The database included 
patients who underwent surgery and those who were con-
servatively managed. We performed a sensitivity analysis 
to include how the patients who did not undergo surgery 
might have influenced the predicted outcome from sur-
gery for all cases of similar Spetzler-Ponce class ubAVMs 
had they undergone surgery and had an adverse outcome 
from surgery. The initial recommendation of the surgeon 
and the decision made by the patient were recorded. The 
risk from surgery for those patients recommended for 
surgery but who were treated elsewhere or refused rec-
ommended management is unlikely to have changed the 
risk occurring in our analyzed series of patients under-
going surgery. However, for those patients recommended 
by the surgeon for conservative treatment because of the 
perceived risk from surgery, predicted outcomes (if sur-
gery had been performed) could be expected to be worse 
than for those with similar Spetzler-Ponce class ubAVMs 
undergoing surgery. Although age and some comorbidity 
are not necessarily a barrier for surgical treatment, for the 
purpose of the sensitivity analysis in this report, we con-
sidered patients younger than 65 years and without sig-
nificant comorbidity as eligible for surgery. These eligible 
patients were incorporated into the sensitivity analysis to 
improve the external validity (generalizability) of the re-
ported risk from surgery.
A limitation of our study is that this is a prospective 
cohort study and patients were not randomly chosen for 
surgery versus conservative management. However, we 
have attempted to provide sufficient information to un-
derstand how this may have impacted outcome, analysis, 
and conclusions.
Methods
Patient Population
This study was approved by the Macquarie Univer-
sity Human Ethics Committee and was performed in ac-
cordance with institutional ethics committee guidelines. 
A prospectively collected database of the senior author 
(M.K.M.) of consecutive patients who harbored bAVMs 
was retrospectively analyzed for the years 1989 to Sep-
tember 2013. The responsibility for entry into the data-
base was that of the senior author. However, the database 
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was accessible to residents, fellows, and occupational 
therapists at the time of assessment and follow-up. The 
database contained demographic, clinical, radiological, 
and treatment-related information. Patients were included 
if they were confirmed to have a ubAVM on MRI, CT 
angiography, or digital subtraction angiography (DSA), 
and if they had at least 1 follow-up review after the ini-
tial referral. The Spetzler-Ponce class was allocated when 
sufficient radiological detail had been obtained to grade 
the ubAVM and was allocated prior to surgery. Hemor-
rhage, in those followed to establish the natural history, 
was considered a new neurological deficit if there was a 
radiological confirmation of hemorrhage and it could be 
related to the ubAVM. The adverse events from surgery 
were considered to be new permanent neurological defi-
cits (assigned within the first 6 weeks of surgery) with a 
modified Rankin Scale (mRS) score > 1 (assigned at last 
follow-up consultation) due to preoperative embolization 
or surgery. The mRS score assigned to each patient was 
subject to open access to fellows, occupational therapists, 
and other neurosurgeons on follow-up consultations.
Risk of Hemorrhage for Untreated ubAVMs
For the study of the risk of hemorrhage, all patients 
with a ubAVM irrespective of management plan were an-
alyzed. Patients were excluded if they had only 1 contact 
date, if they were treated on the same day of referral, if 
they did not have a parenchymal bAVM, if they had a his-
tory of hemorrhage from the bAVM, or if they presented 
with hemorrhage from the bAVM. For the Kaplan-Meier 
analysis of the risk of hemorrhage for this study group, 
the initial date was taken as the first of either the available 
date of referral or first consultation. The event was hem-
orrhage caused by the bAVM (confirmed by CT scan or 
MRI). In the absence of an event, the cases were censored 
at the first of either the first date of treatment (by emboli-
zation, focused irradiation, or surgery) or last follow-up. 
Analyzed ubAVM characteristics were 1) presentation 
with and without seizure; 2) presentation with and with-
out neurological deficits (unrelated to seizure or hemor-
rhage); 3) presence or absence of aneurysm (intranidal or 
located on feeding arteries) on initial DSA; 4) age (as a 
continuous variable); 5) supratentorial versus infratento-
rial location; 6) deep (either brainstem or bAVM with no 
pial surface) versus superficial location; 7) presence or 
absence of exclusive deep venous drainage; 8) maximum 
size (as a continuous variable); and 9) sex.
Risk From Surgery for ubAVMs
The outcomes from surgery leading to a new neuro-
logical deficit with last review mRS score > 1 (as well as 
mRS score > 2) was determined for ubAVMs using the 
Spetzler-Ponce grading system. Analysis was first made 
for patients undergoing surgery. In addition, a sensitivity 
analysis was performed incorporating patients undergo-
ing surgery with the addition of eligible patients (< 65 
years and without significant comorbidity) who were not 
surgically treated because of perceived risk from surgery 
(as recorded at the time of the initial management deci-
sion). These added patients who did not undergo surgery 
were assumed to have an adverse outcome for the purpose 
of the sensitivity analysis. The surgery group included pa-
tients who had preoperative embolization. Adverse out-
comes attributed to embolization were included as surgi-
cal adverse events.
Statistical Analysis
Statistical analysis was performed using Prism soft-
ware (version 6, GraphPad Software Inc.) and IBM SPSS 
Statistics (version 21, IBM Corp.). For the risk of hemor-
rhage from untreated ubAVMs, univariate Cox regression 
was performed for each variable to calculate the hazard 
ratios and 95% confidence intervals. For the risk from sur-
gery analysis, comparison by Spetzler-Ponce groups was 
performed using the Pearson chi-square test for categori-
cal variables and ANOVA for continuous variables. A sta-
tistical significance level of p < 0.05 was used throughout.
Results
From 760 consecutive patients with bAVMs, 427 
patients with ubAVMs were identified. The other 333 
patients had a history of hemorrhage. The flowchart of 
analysis is provided in Fig. 1.
Risk of Hemorrhage for ubAVMs
Of the 427 patients with a ubAVM, 377 were ana-
lyzed for the risk of hemorrhage. Fifty patients were ex-
cluded as they were either treated on the day of referral or 
were reviewed on only 1 occasion. The mean time inter-
val between initial referral and censoring (that is, the first 
of either the 1st day of treatment or last day of follow-up) 
or event (hemorrhage) was 270 days (range 1–5840 days), 
for a total of 279 case-years of follow-up.
Hemorrhage after referral, unrelated to treatment, 
occurred in 16 patients (Table 1). The overall outcomes 
from hemorrhage were a permanent downgrade in func-
tion to an mRS score > 1 in 88% (95% CI 63%–98%; 
14 of 16 patients) and an mRS score > 2 in 69% (95% 
CI 44%–86%; 11 of 16 patients), including death in 31% 
(95% CI 14%–56%; 5 of 16 patients). The baseline char-
acteristics for the patients with a ubAVM and the vari-
ables examined are reported in Table 2. For the entire 
group, the number of patients at risk had declined to 20 
by 5 years. The cumulative rate of ubAVM hemorrhage 
was 8.1% at 1 year using the Kaplan-Meier product-limit 
method and 5.7% if calculated as the number of patients 
with new hemorrhage during follow-up divided by case-
years of follow-up. At 5 years, the cumulative rate of 
ubAVM hemorrhage was 11.5% using the Kaplan-Meier 
product-limit method. This gives an annualized risk of 
first hemorrhage of 2.3% over the first 5 years. The cu-
mulative risk of hemorrhage for different times and the 
number of cases at risk from the study cohort can be seen 
in Table 3 along with a literature review. The risk for the 
first 17 years from referral can be seen in Fig. 2.
Influence of Variables in Predicting Hemorrhage of ubAVMs
Of the 9 variables examined by univariate Cox re-
gression, deeply located (brainstem or not presenting on 
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any pial surface) ubAVMs had a significantly shorter time 
to hemorrhage (p = 0.032, HR 3.78 [95% CI 1.12–12.72]) 
(Table 2). However, the significance of this result needs 
to be treated with caution due to the number of variables 
examined (9) and the low number of events (4) occurring 
in the deep ubAVM group. Aneurysms were known to be 
present in 32% (119 of 377) of cases. This was not sig-
nificant in predicting subsequent hemorrhage (p = 0.98). 
None of the 3 variables contributing to the Spetzler-Ponce 
class was significant in predicting the time to hemorrhage.
Sensitivity Analysis of the Risk From Surgery (With or 
Without Preoperative Embolization)
Of the 427 patients with a ubAVM, 368 were included 
in this analysis. Fifty-nine patients were excluded because 
they were treated by embolization only or were treated 
elsewhere (including those treated by focused irradiation). 
There was no case in which surgery was planned but not 
performed due to subsequent major adverse events from 
diagnostic DSA or embolization. Of these 368 patients, 
27 eligible patients (< 65 years and no significant comor-
bidity) did not undergo surgery because of perceived risk 
of operative complications. There were no eligible pa-
tients excluded from surgery for a Spetzler-Ponce Class A 
ubAVM. For Spetzler-Ponce Class B ubAVMs, 2 eligible 
patients did not undergo surgery because of perceived 
risk of operative complications. For Spetzler-Ponce Class 
C ubAVMs, 25 eligible patients did not undergo surgery 
because of perceived risk of operative complications. The 
comparison between the results from surgery and that for 
the sensitivity analysis is shown in Fig. 3.
For patients with Spetzler-Ponce Class A ubAVMs 
treated by surgery, 1.6% (95% CI 0.3%–4.8%; 3 of 190 
patients) experienced a new permanent neurological defi-
cit from surgery with an mRS score > 1 at last follow-
up. For Spetzler-Ponce Class A ubAVMs, new permanent 
neurological deficits with an mRS score > 2 at last follow-
up were caused by surgery in 0.5% (1 of 190 [95% CI < 
0.1%–3.2%]). Five patients with Spetzler-Ponce Class A 
ubAVMs were recommended for conservative manage-
ment. These patients were either elderly (4 patients, 69–78 
years) or had a significant comorbidity (1 patient with 
terminal liver failure). There were no eligible patients ex-
cluded from surgery because of perceived risk for Spetz-
ler-Ponce Class A ubAVMs. The breakdown of the char-
acteristics of cases as analyzed is presented in Table 4. 
The median time between referral and surgery for Spetz-
ler-Ponce Class A ubAVMs was 27 days (25th percentile 
and 75th percentile of 10 and 60 days, respectively).
For patients with Spetzler-Ponce Class B ubAVMs 
treated by surgery, 14.0% (95% CI 8.6%–22.0%; 15 of 
107 patients) experienced a new permanent neurological 
deficit with an mRS score > 1 at last follow-up from either 
embolization (2 cases) or surgery (14 cases; 13.1% [95% 
CI 7.8%–20.9%], including 1 patient who experienced 
2 adverse events related to both preoperative emboliza-
tion and surgery). For Spetzler-Ponce Class B ubAVMs 
treated by surgery, 2.8% (95% CI 0.6%–8.3%; 3 of 107 
Fig. 1. Flowchart analysis. SPC = Spetzler-Ponce Class.
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patients) experienced a new permanent neurological 
deficits with an mRS > 2 at last follow-up from either 
embolization (1 case) or surgery (3 cases; 2.8% [95% CI 
0.6%–8.3%], including 1 patient who experienced 2 ad-
verse events related to both preoperative embolization 
and surgery). Twenty-two patients with Spetzler-Ponce 
Class B ubAVMs were recommended for conservative 
management or were treated elsewhere. Of these, 2 (1.8% 
of 109 combined patients at increased risk and patients 
undergoing surgery) who were eligible for surgery were 
excluded because of perceived increased risk from sur-
gery. The breakdown of the characteristics of patients as 
analyzed is presented in Table 4. Had patients who were 
excluded because of perceived risk from surgery under-
gone surgery and experienced an adverse outcome, the 
risk of a new permanent neurological deficit with an mRS 
score > 1 would have been 15.6% (95% CI 9.9%–23.7%; 
17 of 109 patients) and for an mRS score > 2 it would have 
been 4.6% (95% CI 1.7–10.6%; 5 of 109 patients). The 
median time between referral and surgery for Spetzler-
Ponce Class B was 38 days (25th percentile and 75th per-
centile of 9 and 94 days, respectively).
For patients with Spetzler-Ponce Class C ubAVMs 
treated by surgery, 38.6% (17 of 44 [95% CI 25.7–53.4%]) 
experienced a new permanent neurological deficit with an 
mRS score > 1 at last follow-up from either emboliza-
tion (2 patients) or surgery (15 patients; 34.1% [95% CI 
21.8%–48.9%]).
For patients with Spetzler-Ponce Class C ubAVMs 
treated by surgery, 15.9% (7 of 44 [95% CI 7.6%–29.7%]) 
experienced new permanent neurological deficits with an 
mRS score > 2 at last follow-up from either emboliza-
tion (2 patients) or surgery (5 patients; 11.4% [95% CI 
4.5%–24.4%]). Forty patients with Spetzler-Ponce Class 
C ubAVMs were recommended for conservative manage-
ment or were treated elsewhere. Of these, 25 patients who 
were eligible for surgery (36.2% of 69 combined patients 
with increased risk and patients undergoing surgery) were 
excluded because of perceived increased risk from sur-
gery. The breakdown of the characteristics of cases as 
analyzed is presented in Table 4. Had patients excluded 
because of perceived risk from surgery undergone sur-
gery and experienced an adverse outcome, the risk of a 
new permanent neurological deficit with an mRS score > 
1 would have been 60.9% (95% CI 49.2%–71.5%; 42 of 69 
patients) and for mRS score > 2 would have been 46.4% 
(95% CI 36.5%–59.4%; 32 of 69 patients). The median 
time between referral and surgery for Spetzler-Ponce 
Class C was 67 days (25th percentile and 75th percentile 
of 36 and 176 days, respectively).
Complete bAVM resection was confirmed by post-
operative DSA in 333 of 341 patients (97.7% [95% CI 
95.4%–98.9%]). Three patients who had a persisting 
bAVM underwent further treatment to achieve DSA-
confirmed complete resection by focused irradiation in 
2 patients and endovascular treatment in 1 patient. Five 
patients died and did not undergo postoperative DSA. All 
patients with Spetzler-Ponce Class A ubAVMs (except for 
the patient who died of myocardial infarction during sur-
gery) had confirmed complete resection of the bAVM by 
postoperative DSA.
Risk of Hemorrhage for Untreated ubAVMs Compared 
With the Sensitivity Analysis of the Risk From Surgery
Superimposing upon the Kaplan-Meier curve (of the 
risk of hemorrhage) the risk from surgery, the crossover 
occurred within 5 months for Spetzler-Ponce Class A 
TABLE 1: Patients experiencing their first bAVM hemorrhage after referral*
Case 
No.
Age (yrs), 
Sex
Spetzler-Martin Grade, 
Side & Location Neurological Presentation
Days Btwn Referral  
& 1st Hemorrhage
Outcome 
mRS Score
Complication Due to 
Surgery Leading to 
mRS Score >1
1 76, M I, rt temporal normal 6 0 none
2 13, M II, lt cerebellum normal, seizure 8 2 none
3 45, M III, lt fronto-parietal normal, seizure 14 6 NA
4 53, M IV, lt basal ganglia normal 56 3 none
5 30, M II, rt parietal normal, seizure 137 6 NA
6 17, M II, rt temporal normal, seizure 194 3 none
7 42, F III, rt frontal normal, seizure 218 6 NA
8 36, F III, rt frontal normal 330 6 NA
9 43, F IV, lt parietal mild hemiparesis & dysphasia 1057 3 none
10 13, F IV, lt thalamic normal 2195 2 NA
11 56, F III, lt frontal mild dysphasia 2436 1 NA
12 35, M V, pons hemiparesis & hemiparesthesia 2607 2 NA
13 63, F III, lt fronto-parietal hemiparesis 2917 4 NA
14 54, M III, lt parietal normal 3065 3 NA
15 44, M III, rt frontal normal 3086 3 NA
16 44, M II, lt cerebellum normal 3263 6 NA
* NA = not applicable because surgery was not performed.
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ubAVMs, between 8 and 9 years for Spetzler-Ponce Class 
B ubAVMs, and did not occur for Spetzler-Ponce Class 
C ubAVMs for outcomes with mRS score > 1 (Fig. 4). 
However, little reliance should be placed on the point of 
crossover if this is predicted to occur beyond 5 years be-
cause of the small number of patients remaining at risk 
at this time.
Superimposing upon the Kaplan-Meier curve (of the 
risk of hemorrhage) the risk from surgery, the crossover 
occurred before 5 months for Spetzler-Ponce Class A 
ubAVMs, between 6 and 8 months for Spetzler-Ponce Class 
B ubAVMs, and beyond 8 years for Spetzler-Ponce Class C 
ubAVMs for outcomes with mRS score > 2 (Fig. 4).
We further examined the relationship between the 
95% confidence intervals for both the natural history and 
sensitivity analysis of surgery (Fig. 4). That is, for this 
analysis, we included both those patients who underwent 
surgery as well as those who were excluded from surgery 
because of risk although eligible (< 65 years and with no 
comorbidity). We wanted to know whether the upper 95% 
risk from surgery (that is, the lower 95% confidence inter-
val of being free of adverse outcomes) crossed the lowest 
95% risk of a hemorrhage causing a deficit (that is, the 
upper 95% confidence interval of being free of adverse 
outcomes). This was specifically performed for outcomes 
with mRS score > 1 and mRS score > 2. The upper 95% 
TABLE 2: Characteristics of 377 patients with ubAVMs with a recorded referral date and subsequent date of hemorrhage or censoring (the 
earliest of last clinical review or treatment)*
Variable
No. of Patients w/ 
Variable (%)
% of Group Developing Hemorrhage 
After Referral (actual no.) p Value† HR (95% CI)‡
sex 0.83 (0.31–2.25)
 M 198 (52.5) 4.5 (9 of 198) 0.711
 F 179 (47.5) 3.9 (7 of 179)
age in yrs (mean 37.4 ± 15.6 yrs) 0.264 (continuous variable) 1.02 (0.99–1.05)
 0–19 49 (13.0) 6.1 (3 of 49)
 20–39 172 (45.6) 1.7 (3 of 172)
 40–59 120 (31.8) 6.7  (8 of 120)
 60–79 35 (9.3) 5.7 (2 of 35)
 >79 1 (0.3) 0 (0 of 1)
location 0.159 2.50 (0.70–8.94)
 infratentorial 23 (6.1) 13 (3 of 23)
 supratentorial 354 (93.9) 3.7 (13 of 354)
location 0.032 3.78 (1.12–12.72)
 deep§ 32 (8.5) 12.5 (4 of 32)
  superficial 345 (91.5) 3.5 (12 of 345)
maximum size 0.282 (continuous variable) 0.85 (0.63–1.14)
 <3 cm 126 (33.4) 1.6 (2 of 126)
 3–6 cm 217 (57.6) 6.0 (13 of 217)
 >6 cm 34 (9.0) 2.9 (1 of 34)
deep venous drainage (exclusive) 0.455 1.62 (0.46–5.72)
 yes 42 (11.1) 7.1 (3 of 42)
 no 335 (88.9) 3.9 (13 of 335)
presentation w/ seizures 0.479 0.70 (0.26–1.89)
 seizures 196 (52.0) 3.6 (7 of 196)
 no seizures 181 (48.0) 5.0 (9 of 181)
presentation w/ neurological deficit 0.161 2.05 (0.75–5.57)
  neurological deficit 63 (16.7) 11.1 (7 of 64)
  no neurological deficit 314 (83.3) 2.9 (9 of 314)
aneurysms (on initial DSA) 0.983 1.01 (0.35–2.93)
 present 119 (31.6) 4.2 (5 of 119)
 absent 258 (68.4) 4.3 (11 of 258)
* NA = not applicable.
† Univariate Cox regression.
‡ Univariate analysis.
§ Deep = brainstem or not located on a pial surface.
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confidence interval for the natural history (of hemorrhage 
leading to a permanent neurological deficit) and the lower 
95% confidence interval of surgery (being free of adverse 
outcomes leading to a permanent neurological deficit) 
were superimposed to identify when the upper 90% con-
fidence (combining the two 95% confidence intervals) of 
surgery risk crossed the natural history risk. The mRS 
score > 1 upper 95% confidence interval was crossed by 
the lower outcome Spetzler-Ponce Class A at 3065 days. 
Such crossing did not occur for either Spetzler-Ponce 
Class B or Spetzler-Ponce Class C ubAVMs. The mRS 
score > 2 upper 95% confidence interval was crossed by 
the lower outcome Spetzler-Ponce Class A ubAVMs at 
1057 days. The mRS score > 2 upper 95% confidence in-
terval was crossed by the lower outcome Spetzler-Ponce 
Class B at 3065 days. Such crossing did not occur for 
Spetzler-Ponce Class C ubAVMs.
Discussion
Our results showed that Spetzler-Ponce Class A 
ubAVMs treated by surgery had a better outcome than 
conservatively managed ubAVMs within a short period of 
time with a high rate of cure. Where the outcome is consid-
ered mRS score > 2, both surgically treated Spetzler-Ponce 
Class A and Spetzler-Ponce Class B ubAVMs had a better 
outcome than conservatively managed ubAVMs within a 
short period of time. Therefore, in this cohort study, it is 
reasonable to conclude that surgery can be superior to con-
servative management for a defined group of patients.
These findings are in stark contrast to the results of 
ARUBA, where treatment was reported to be significant-
ly worse than conservative management for ubAVMs.17 
Although considered a high standard of evidence, for a 
multicentered RCT to be generalizable (that is, have ex-
ternal validity), the application of ethical equipoise must 
result in a sum of subjects reflective of the real world. The 
large number of centers agreeing to participate but fail-
ing to enroll patients either reflects these centers’ inability 
to recruit patients (despite the selection of these centers 
for this capability) or an inability to apply ethical equi-
poise. A major difference in how ubAVMs were managed 
between our study and ARUBA was that our interven-
tions analyzed were 100% surgery, with surgery alone as 
the sole interventional treatment in 84% of patients (285 
of 341 patients; 56 patients underwent preoperative em-
bolization); compared with ARUBA where surgery was 
performed in 16% (18 of 114) of interventions and sur-
gery alone was the sole interventional treatment in 4% 
(5 of 114) of interventional cases. As such, ARUBA can-
not be considered a study assessing the role of surgery 
for ubAVMs.17 Furthermore, the claim from ARUBA that 
the “baseline characteristics of trial participants are much 
the same as those representative of population-based co-
horts” is true for sex, age, and presentation (factors that 
are unlikely to impact upon treatment bias) but is not nec-
essarily true for those characteristics that influence the 
risk of surgery. Comparing characteristics of ARUBA-
enrolled patients with our patients reveals the following: 
Deep venous drainage was absent in 66% of ARUBA pa-
tients (95% CI, 59–72%), whereas it was absent in 89% 
of our patients (95% CI 85%–92%); Spetzler-Ponce Class 
C classification was present in 10% of ARUBA patients 
(95% CI 7%–15%), whereas it was present in 22% of 
our patients (95% CI 18%–27%); and AVM < 3 cm was 
present in 62% of ARUBA patients (95% CI 55%–68%), 
whereas it was present in 33% of our patients (95% CI 
29%–38%). Although referral bias for complex ubAVMs 
may have occurred in our case series, the differences may 
also be explained by distortion of patients considered to 
TABLE 3: Risk of hemorrhage reported in the literature (case series reporting more than 25 ubAVM cases) as well as present series*
Authors & Year
Initial No. of 
ubAVM  
Cases at Risk
% 12-Mo Risk of 
1st Hemorrhage 
% 5-Yr Risk of 
1st Hemorrhage 
% Averaged Annualized 
Risk of 1st Hemorrhage 
From ubAVM 
Yrs of Follow-Up to 
Which the Annual 
Risk Applies
Method of 
Calculation
Graf et al., 1983 66 2 14 2–3 20 Kaplan-Meier
Brown et al., 1988 168 1.3 8.5 2.3 15 Kaplan-Meier
Pollock et al., 1996 119 1.9† 9.5† 1.9 NA patient-yr method
Halim et al., 2004 423 3 9 2 10 Kaplan-Meier
Stapf et al., 2006 340 1.3† 5‡ 1.3 NA Kaplan-Meier
Yamada et al., 2007 146 3.1† 15.5† 3.1 5 patient-yr method
Kim et al., 2007 781§ 1.4† 7† 1.4 5 Kaplan-Meier
da Costa et al., 2009 420 3.6¶ 18‡ 3.6 5 patient-yr method
Hernesniemi et al., 2008 99 2.3† 10 2.3 5 patient-yr method
ARUBA, 201317 125 2.2 12‡ 2.3 5 Kaplan-Meier
present series 377 8.1 11.5 2.3 5 Kaplan-Meier
* NA = not available.
†  Derived from the averaged annualized risk of first hemorrhage from ubAVM.
‡  Approximated from Kaplan-Meier figure provided in publication.
§ Some cases are likely to have been included in earlier report (Halim et al.).
¶ Seizure presentation.
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meet clinical equipoise enrolled in ARUBA. Given that 
selection bias may have occurred in ARUBA, the gen-
eralizability of conclusions needs to be questioned. This 
justifies the continued examination of case series at this 
time.
Natural History
Because of the lower risk of hemorrhage from 
ubAVMs compared with those presenting with hemor-
rhage, concern has been raised as to whether treatment of 
ubAVMs is justified.17 A meta-analysis found an annual 
ubAVM hemorrhage rate of 2.2% (95% CI 1.7%–2.7%).9 
Of interest for ubAVMs, the rate of hemorrhage has been 
found to be considerably higher during the 1st year af-
ter diagnosis.11,12,33 In a prospective study from Japan, 
the rate of first hemorrhage was greater during the first 
12 months after presentation (4.8%).12 As there may be 
a nonlinear relationship between time from presentation 
and hemorrhage, the time from diagnosis to enrollment 
in prospective studies is important. As there was often 
a delay between referral and treatment, we used all our 
potential 377 patients with a ubAVM in the analysis of the 
risk of hemorrhage. Although our method using Kaplan-
Meier product-limit method found an 8.1% 1st year risk 
of hemorrhage, when utilizing the method of these stud-
ies (calculated as the number of patients with hemorrhage 
during follow-up divided by case-years of follow-up) the 
risk of hemorrhage in our series is 5.7%. This is marginal-
ly greater than previously published series for the 1st year 
risk of hemorrhage. The 11.5% 5-year risk of first hemor-
rhage is similar to that reported in the literature (Table 
3). The cumulative hemorrhage rate found in ARUBA at 
5 years was estimated to be approximately 12% from the 
Kaplan-Meier figure provided. Considering the number at 
risk in our study at each stage of follow-up, we believe our 
Fig. 2. Kaplan-Meier curves and numbers at risk for the 377 patients with bAVMs enrolled in the risk of hemorrhage study. H = 
hemorrhage.
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results are reliable for the first 5 years from initial refer-
ral. However, Hernesniemi and colleagues, who provide 
the longest long-term analysis (with a mean of 13.5 years) 
of 99 ubAVMs, found a cumulative first hemorrhage risk 
of 10% and 29% at 5 and 20 years, respectively.11 They 
excluded patients with less than 1 month of follow-up 
(which differs from our own analysis). On an annualized 
basis, our results suggest a risk of first hemorrhage of 
2.3% per year over 5 years. This is within the range of 
literature estimates (Table 3) and is similar to 2.2% calcu-
lated by Gross and Du in their meta-analysis.9
Our finding that ubAVMs had a slightly greater risk 
of rupture in the first 12 months after diagnosis (Table 
3) than previously reported may be explained by the in-
clusion of patients from the time of referral, capturing 
patients who otherwise would have been excluded if the 
commencement of the database had coincided with ad-
mission to hospital. That a higher rate of hemorrhage oc-
curs early in some series may be explained by a small 
number of patients presenting with clinical symptoms 
due to changes within the ubAVM that alter the hemo-
dynamics (for example, venous outflow stenosis or occlu-
sion) that might predispose to hemorrhage.6,15,16,32 Such 
changing hemodynamics would not be captured in most 
database interrogations. The importance of knowing the 
time from diagnosis in estimating the future risk needs to 
be considered.
The clinical consequence of hemorrhage for ubAVMs 
in our experience was significant, resulting in a perma-
nent adverse outcome with mRS score > 2 in more than 
two-thirds (of these, nearly half resulted in death). This is 
in the range of outcomes reported in the literature. Of 77 
patients who suffered hemorrhage, Crawford et al. report-
ed a 25% mortality and 19% incidence of hemiparesis.3 
Brown and colleagues reported a similar 29% mortality 
and 16% morbidity from hemorrhage in follow-up.2 Ondra 
and colleagues reported that 85% of 64 patients died or 
sustained major permanent morbidity.20 Da Costa and col-
leagues reported 89 hemorrhages after enrollment to their 
bAVM database (both unruptured and ruptured bAVMs) 
for a 6% mortality and 35% significant permanent disabil-
ity.4 It is reasonable to assume that approximately half of 
those experiencing hemorrhage from a ubAVM will have 
a significant permanent deficit or fatal outcome.
Arranging a classification for ubAVMs according to 
characteristics that impact upon risk of hemorrhage is an 
appealing strategy. Stapf and colleagues identified a com-
bination of a number of factors that may predict a high 
rate of hemorrhage, and the corollary was also proposed 
that in the absence of these factors the risk of hemorrhage 
is very low.28 Our results suggest that such classifica-
tion would have limited utility in predicting the risk of 
ubAVM hemorrhage during the first years after diagnosis 
for our cohort. In our cases, deep location had a weak 
predictive value and no other variable was significant.
Surgical Outcomes
We have previously reported the lower risk for sur-
gery for Spetzler-Ponce Class A bAVMs compared 
with Spetzler-Ponce Class B and Spetzler-Ponce Class 
C bAVMs. Also, we previously reported that very few 
Spetz ler-Ponce Class A bAVMs were not recommended 
for surgery due to perceived risks,5 which differed from 
the higher grades where a number of cases were selected 
for conservative management because of the perceived 
risk from surgery. Therefore, to assess the generaliz-
able risk from surgery for all Spetzler-Ponce Class B and 
Spetzler-Ponce Class C bAVMs, consideration needs to 
be made of those eligible patients who do not undergo 
surgery because of perceived risk from surgery. The 5 pa-
tients with Spetzler-Ponce Class A bAVMs recommended 
for conservative management were either elderly or had 
comorbidity suggesting an unlikelihood of benefit from 
surgery and were considered not eligible for surgery. Our 
findings that Spetzler-Ponce Class A ubAVMs treated by 
surgery had a new permanent neurological deficit (mRS 
score > 1 outcome) of 1.6% due to surgery can be general-
ized to all eligible cases (treated by surgery or not). With 
regard to Spetzler-Ponce Class B ubAVMs, 2 of 109 eli-
gible patients (< 65 years and without significant comor-
bidity) were excluded due to a perceived higher risk from 
surgery. Had both of these cases been incorporated in the 
surgical outcomes and had an adverse outcome, 15.6% of 
these cases would have had an adverse outcome and in 
Fig. 3. Sensitivity analysis and comparison between the adverse 
outcomes from surgery for 341 ubAVMs and that projected if 27 cases 
excluded from surgery underwent surgery and experienced an adverse 
outcome.
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4.6% of cases would this have led to an mRS score > 2. 
The results for Spetzler-Ponce Class C ubAVMs cannot be 
generalized due to the large number of potentially eligible 
patients (< 65 years and without significant comorbidity) 
excluded because of perceived higher risk from surgery. 
Had these patients been incorporated in the surgical out-
comes and had an adverse outcome, the adverse outcome 
rate would be closer to 61%, which is greater than the 
39% seen for those cases that were selected for surgery.
Despite the demonstration that the Spetzler-Martin 
grading system25 is a good way of stratifying the risks 
from surgery, this has not been reported for ubAVMs be-
TABLE 4: Characteristics of cases included in the surgical and in the sensitivity analysis groups*
Variable Analyzed Groups SPC A SPC B SPC C p Value†
no. of cases total operated & unoperated 214 129 84
total cases undergoing surgery w/ or w/o 
preop embolization
190 107 44
features of surgical 
cases
mean pt age in yrs 39.5 ± 15.7 33.3 ± 13.4 37.0 ± 14.7 0.004
mean ubAVM diameter in cm 2.7 ± 1.2 4.3 ± 1.5 5.9 ± 1.6 <0.001
female 45.8% (87 of 190) 52.3% (56 of 107) 47.7% (21 of 44) 0.555
presentation of surgical 
cases
seizure 47.9% (91 of 190) 57.9% (62 of 107) 56.8% (25 of 44) 0.202
neurological symptoms (other than seizure) 12.1% (23 of 190) 17.8% (19 of 107) 20.5% (9 of 44) 0.232
AVM features of surgical 
cases
eloquent 17.9% (34 of 190) 64.5% (69 of 107) 81.8% (36 of 44) <0.001
deep location 5.8% (11 of 190) 6.5% (7 of 107) 11.4% (5 of 44) 0.412
exclusive deep venous drainage 7.4% (14 of 190) 10.3% (11 of 107) 18.2% (8 of 44) 0.089
aneurysm 26.3% (50 of 190) 38.3% (41 of 107) 45.5% (20 of 44) 0.016
infratentorial 5.8% (11 of 190) 6.5% (7 of 107) 4.5% (2 of 44) 0.892
SMG of surgical cases I: % of SPC A 34.7% (66 of 190) — —
II: % of SPC A 65.3% (124 of 190) — —
III: % of SPC B — 100% (107 of 107) —
IV: % of SPC C — — 77.3% (34 of 44)
V: % of SPC C — — 22.7% (10 of 44)
follow-up of surgical 
cases
mean mos following surgery 31.0 ± 36.3 34.9 ± 37.7 36.3 ± 36.1 0.566
adverse outcomes of 
treatment
mRS score 2 1.1% (2 of 190) 11.2% (12 of 107) 22.7% (10 of 44)
mRS score 3–5 — 1.9% (2 of 107)‡ 9.1% (4 of 44)
dead 0.5% (1 of 190) 0.9% (1 of 107) 6.8% (3 of 44)
mRS score >1 w/in SMG subgroup (95% CI) 1.6% (0.3–4.8%) 14.0% (8.6–22.0%) 38.6% (25.7–53.4%)
mRS score >2 w/in SMG subgroup (95% CI) 0.5% (<0.1–3.2%) 2.8% (0.6–8.3%) 15.9% (7.6–29.7%)
cause of adverse 
outcomes
preop embolization w/in SPC group 0% (0 of 11) 9.1% (2 of 22)‡ 8.7% (2 of 23)
surgery 1.6% (3 of 190) 13.1% (14 of 107)‡ 34.1% (15 of 44)
excluded from surgery & 
sensitivity analysis
treated elsewhere or by other means or 
poor neurological condition
9.3% (20 of 214) 14.0% (18 of 129) 15.5% (13 of 84) 0.262
ineligible because of age >65 yrs or comor-
bidities
1.9% (4 of 214) 1.6% (2 of 129) 2.4% (2 of 84)
included in sensitivity 
analysis
unoperated cases due to surgical risk 
added to cases undergoing surgery
190 109 69
assumption that all 
eligible cases would 
have adverse out-
come for the purpose 
of sensitivity analysis
mRS score >1 including all eligible cases  
w/in SPC subgroup (95% CI)
1.6% (0.3–4.8%) 15.6% (9.9–23.7%) 60.9% (49.2–71.5%)
mRS score >2 including all eligible cases  
w/in SPC subgroup (95% CI)
0.5% (<0.1–3.2%) 4.6% (1.7–10.6%) 46.4% (35.1–58.0%)
time from referral to 
surgery
median no. of days (25th–75th percentile) 27 (10–60) 38 (9–94) 67 (36–176)
* Values in parentheses are number of cases (%) unless noted otherwise. Mean values are presented as the mean ± SD. pt = patient; SMG = Spetzler-
Martin grade; SPC = Spetzler-Ponce class.
† Chi-square test for categorical variable and 1-way ANOVA test for continuous variables.
‡ One patient experienced 2 adverse events, related to both preoperative embolization and surgery.
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fore. Our finding that the Spetzler-Martin grading system 
applied to ubAVM surgery was useful in stratifying the 
incidence of adverse outcomes.
A proportion of the morbidity and mortality arose as 
a consequence of preoperative embolization. We have pre-
viously published our results of embolization and the lack 
of evidence of benefit from preoperative embolization for 
cases of Spetzler-Ponce Class A ubAVMs.18,19 Consider-
ation should be given to early surgery, elimination of the 
use of embolization, and perhaps reduction in the use of 
preoperative diagnostic DSA for Spetzler-Ponce Class A 
ubAVMs to reduce adverse outcomes from all causes in 
this group.
For Spetzler-Ponce Class B and Spetzler-Ponce Class 
C ubAVMs, the risk of an adverse outcome from surgery 
is high. Therefore, recommending management for these 
patients remains a highly nuanced process and may not 
be made for several years after first referral. Despite the 
high morbidity for this group, the 1% and 7% mortality 
for Spetzler-Ponce Class B and Spetzler-Ponce Class C 
ubAVMs, respectively, are likely lower than the long-term 
mortality if untreated. This mortality may come into con-
sideration in the decision making for some patients (par-
ticularly younger patients).
Comparing Surgery and Conservative Management
We believe that we can generalize the conclusion that 
our results confirm that Spetzler-Ponce Class A ubAVMs 
treated by surgery have a better outcome than conser-
vatively managed ubAVMs. This was investigated by 
looking at the most optimistic boundary of our results 
of natural history (the upper 95% confidence interval 
for not experiencing an adverse outcome) with the most 
pessimistic boundary of surgery (the lower 95% confi-
dence interval for not experiencing an adverse outcome). 
Superimposing these 95% boundaries, for mRS score > 
Fig. 4.  Modified Rankin Scale score outcomes for surgery, sensitivity analysis of surgery, and hemorrhage from ubAVM. The 
mRS outcome of Kaplan-Meier percentage of natural history (377 patients) is superimposed on sensitivity analysis of surgery. A 
total of 190 patients had Spetzler-Ponce Class A ubAVMs, 109 had Spetzler-Ponce Class B ubAVMs, and 69 had Spetzler-Ponce 
Class C ubAVMs. KM = Kaplan-Meier.
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1 there was crossover within 9 years and for mRS > 2 
crossover was within 3 years of surgery. Therefore, our 
results suggest a 90% likelihood (combining the two 95% 
confidence intervals) that there is a benefit for surgery 
over conservative treatment within 3 years of treatment 
for our cases. The superimposition of sensitivity analysis 
upon the natural history curve suggests a tendency to an 
advantage for Spetzler-Ponce Class B ubAVMs; however, 
using the higher level of confidence by superimposing the 
95% boundaries, the outcome for surgery for Spetzler-
Ponce Class B and Spetzler-Ponce Class C ubAVMs may 
not be better than conservative management of ubAVMs. 
However, there are a number of complex factors that may 
come into play for individual patients (such as the like-
ly lower mortality rate from surgery) that result in the 
recommendation for surgery despite the daunting mor-
bidity. Although we have shown that for selected cases 
surgery can be better than medical management, a weak-
ness of our results relates to the generalizability to other 
surgeons and institutions. An avenue for future research 
is to explore results from larger administrative areas to 
see whether results for the population of patients being 
treated by surgery are better than medical management.
Conclusions
Our study suggests that surgical outcomes for Spetz-
ler-Ponce Class A ubAVMs can be better than those for 
conservative management. The difficulty in performing 
RCTs is clear from ARUBA. The prospect of mounting 
a future RCT becomes increasingly difficult as the win-
dow of ethical equipoise continues to close because there 
is increasing evidence for a specific management path-
way (even if this evidence is from cohort series). Future 
research in this area should concentrate on the selection 
process for management pathways that provide enough 
context to inform consensus and identify those that can 
best be managed by surgery.
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Surgical management of unruptured 
cerebral arteriovenous malformations
MOHAMED SAMY ELHAMMADY, M.D., 
AND ROBERTO C. HEROS, M.D.
Department of Neurosurgery, University of Miami, Florida
This issue of the Journal of Neurosurgery includes 
an excellent paper by Bervini et al. from Professor Mor-
gan’s service at Macquarie University in Sydney, Aus-
tralia.2 This well-respected group has one of the largest 
experiences in the world with cerebral arteriovenous 
malformations (AVMs). In this study, the authors sought 
to ascertain the natural history of unruptured brain AVMs 
with regard to risk of rupture as well as the morbidity 
and mortality associated with resection. The authors 
UHWURVSHFWLYHO\ LGHQWLÀHG DOO SDWLHQWV ZLWK XQUXSWXUHG
brain AVMs who were referred to their institution from 
a prospectively maintained AVM database consisting 
of both treated and untreated lesions. Over a 24-year 
period, a total of 427 patients with unruptured cerebral 
$90V ZHUH LGHQWLÀHG $OO SDWLHQWV ZLWK PRUH WKDQ
1 day of follow-up (n = 377) were analyzed for risk of 
hemorrhage, irrespective of the management plan, from 
the date of initial consultation or referral to the date of 
last available follow-up or until the initiation of treatment. 
5DGLRORJLFDOO\ FRQÀUPHG KHPRUUKDJH XQUHODWHG WR
treatment occurred in 16 patients during a total of 279 
case-years of follow-up. Permanent disability following 
KHPRUUKDJHUHVXOWHGLQDPRGLÀHG5DQNLQ6FDOHP56
score > 1 in 88% (14 cases), mRS score > 2 in 69%, 
and death in 31% of the patients. The cumulative rate 
of hemorrhage using Kaplan-Meier analysis at 1 and 5 
years was 8.1% and 11.5%, respectively. The annualized 
ULVNRIKHPRUUKDJHRYHUWKHÀUVW\HDUVZDV7KH
RQO\YDULDEOHDVVRFLDWHGZLWKDVLJQLÀFDQWO\VKRUWHUWLPH
to hemorrhage was deep location by univariate analysis.
The risk from resection was assessed in 2 ways. First, 
the authors analyzed the surgical outcomes in patients 
who actually underwent resection based on AVM grade. 
7KHDXWKRUVFODVVLÀHG$90VDFFRUGLQJWR6SHW]OHU3RQFH
Class where Class A comprised Spetzler-Martin Grade 
I and II lesions, Class B comprised Spetzler-Martin 
Grade III lesions, and Class C comprised Spetzler-Martin 
*UDGH,9DQG9OHVLRQV&RPSOLFDWLRQVZHUHGHÀQHGDV
DQ\ SHUPDQHQW QHXURORJLFDO GHÀFLWV IROORZLQJ VXUJHU\
including those related to preoperative embolization, 
that resulted in an mRS score > 1 at last follow-up. The 
authors then performed an interesting sensitivity analysis 
to estimate the true risk of surgery for all AVM grades 
and not only those selected based on a perceived favorable 
ULVNEHQHÀWUDWLR7KHDXWKRUVLQFOXGHGSDWLHQWVZKRZHUH
eligible for surgery but did not undergo resection because 
of perceived excess surgical morbidity with those who 
actually underwent resection. Patients were considered 
eligible for surgery if they were younger than 65 years 
DQGGLGQRWKDYHVLJQLÀFDQWFRPRUELGLWLHV7KHVHDGGHG
unoperated cases were assumed to have an adverse 
outcome for the purpose of the sensitivity analysis. 
For patients with Spetzler-Ponce Class A lesions 
treated by surgery (n = 190), the risk of a new permanent 
GHÀFLWUHVXOWLQJLQDQP56VFRUH!RUP56VFRUH!
was 1.6% and 0.5%, respectively. None of the eligible 
patients with Spetzler-Ponce Class A lesions were 
excluded because of perceived excessive surgical risk and 
thus a sensitivity analysis was not performed. For patients 
with Spetzler-Ponce Class B lesions treated by surgery (n 
 WKHULVNRIDQHZSHUPDQHQWGHÀFLWUHVXOWLQJLQDQ
mRS score> 1 was 14% and mRS score > 2 was 2.8%. 
Two eligible patients with Spetzler-Ponce Class B lesions 
were excluded because of perceived excessive surgical 
risk. The sensitivity analysis showed that if these cases 
had been included the risk of a new permanent neurologi-
FDOGHÀFLWUHVXOWLQJLQDQP56VFRUH!RUP56VFRUH!
would have been as high as 15.6% and 4.6%, respectively. 
For patients with Spetzler-Ponce Class C lesions treated 
E\VXUJHU\Q WKHULVNRIDQHZSHUPDQHQWGHÀFLWUH-
sulting in an mRS score > 1 was 38.6% and an mRS score 
!ZDV7ZHQW\ÀYHHOLJLEOHSDWLHQWVZHUHGHQLHG
surgery due to perceived excessive surgical morbidity. The 
sensitivity analysis showed that if these cases had been 
LQFOXGHGWKHULVNRIDQHZSHUPDQHQWQHXURORJLFDOGHÀFLW
resulting in an mRS score > 1 or mRS score > 2 would 
have been as high as 60.9% and 46.4%, respectively.
The authors then superimposed the risk of surgery re-
sulting in an mRS score > 1 upon the Kaplan-Meier curve 
of the risk of hemorrhage and found that the crossover 
occurred before 5 months for Spetzler-Ponce Class A le-
sions and between 8 and 9 years for Spetzler-Ponce Class 
B lesions but did not occur for Spetzler-Ponce Class C le-
sions. When surgical outcomes resulting in an mRS score 
> 2 were superimposed, the crossover occurred before 5 
months, between 6 and 8 months, and beyond 8 years for 
Spetzler-Ponce Class A, B, and C lesions, respectively. 
The authors concluded that surgery for Spetzler-Ponce 
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Class A unruptured cerebral AVMs beats the natural his-
WRU\7KH\IXUWKHUFRQÀUPHGWKLVFRQFOXVLRQE\VXSHULP-
posing the most optimistic boundary of the natural history 
WKHXSSHUFRQÀGHQFHLQWHUYDOIRUQRWH[SHULHQFLQJ
an adverse outcome) with the most pessimistic boundary 
RIWKHVXUJLFDOVHQVLWLYLW\DQDO\VLVWKHORZHUFRQÀ-
dence interval for not experiencing an adverse outcome) 
and found that the crossover occurred within 9 years for 
mRS score > 2 and within 3 years for mRS > score 1, 
VXJJHVWLQJDFKDQFHRIVXUJLFDOEHQHÀWRYHUFRQVHU-
vative treatment within 3 years for unruptured Spetzler-
Ponce Class A AVMs. On the other hand, a similar analy-
sis for Spetzler-Ponce Class B and Spetzler-Ponce Class 
C lesions suggested that surgery might not be better than 
conservative management.
The article, which is very well written and discussed, 
has some limitations, which were acknowledged by the 
authors. This was a nonrandomized retrospective analysis 
of a prospective cohort of patients. The natural history 
data presented by the authors must be interpreted with 
some skepticism. They studied patients from the time of 
diagnosis to the time of treatment, hemorrhage, or the 
date of the last follow-up in those patients who did not 
have hemorrhage or treatment. In this group of patients, 
the average time between initial referral and treatment, 
hemorrhage, or last follow-up was 270 days with a range 
of 1 to 5840 days. Why such a delay in treatment in these 
patients? One could conceive that there was a bias in de-
laying treatment in those patients who for one reason or 
another were suspected to have a lesser risk of hemor-
rhage. Nevertheless, the risk of hemorrhage of approxi-
PDWHO\SHU\HDUGXULQJWKHÀUVW\HDUVRIIROORZXS
calculated in this fashion by these authors is very similar 
WRWKDWIRXQGLQRWKHUVWXGLHVWKDWDGGUHVVVSHFLÀFDOO\WKH
natural history of unruptured AVMs, as discussed and 
referenced by the authors. 
More straightforward are the data provided by the 
authors in their surgical results. Clearly, it could be ar-
gued that the results of a highly skilled and extremely 
experienced neurovascular surgeon such as Professor 
Morgan cannot be generalized. However, his results are 
comparable to those reported in several series, including 
our own.1,4,6–8 Still, it is very likely that these excellent 
results can only be achieved in centers with considerable 
experience in the treatment of AVMs, and, in this respect, 
the results reported in this study may not be generaliz-
able; however, should not most patients with such relative-
ly uncommon and complicated lesions as cerebral AVMs 
be referred for elective treatment to experienced centers? 
Undoubtedly, the design of this retrospective study 
was intended as a direct challenge to the recently reported 
A Randomized Trial of Unruptured Brain Arteriovenous 
Malformations (ARUBA) results. We have commented 
in some detail in a recent editorial on the need to exert 
caution in the interpretation of the results of the ARUBA 
study and we will not repeat that discussion here.3 The 
fact is that, despite the widely discussed limitations of the 
results of the ARUBA studies, many have interpreted such 
results as indicative of the fact that no unruptured cere-
bral AVM should be treated at all. Hence, the importance 
of the study by Professor Morgan and his colleagues that, 
when supplemented by similar results reported in other 
large series, provide robust support for recommending 
WUHDWPHQW VSHFLÀFDOO\ H[FLVLRQ WR DOO UHODWLYHO\ \RXQJ
and healthy patients with an unruptured Spetzler-Martin 
Grade I or II AVM. The results of treatment, which is 
frequently multimodality, with Spetzler-Martin Grade IV 
and V AVMs, even in the best hands, as evidenced in this 
particular study, strongly argue against recommending 
treatment to patients with unruptured high-grade AVMs. 
As many have discussed, including ourselves in a recent 
editorial,3,5 decision making with Spetzler-Martin Grade 
,,,PDOIRUPDWLRQVLVLQGHHGGLIÀFXOWVLQFHWKLVLVDYHU\
KHWHURJHQHRXVJURXSRI OHVLRQV6XIÀFH WRVD\ WKDWZLWK
these AVMs, treatment decisions must be highly indi-
vidualized and that in general, when dealing with unrup-
tured Grade III AVMs, a relatively conservative attitude 
is desirable. 
We thank Professor Morgan and his group for pro-
viding us with an excellent article that, we believe, will 
EHKLJKO\LQÁXHQWLDO
(http://thejns.org/doi/abs/10.3171/2014.5.JNS14240)
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We thank the authors for their thoughtful response to 
our article. Two issues raised by the authors that need to 
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be addressed include delay to treatment and the general-
izability of the surgical results.
The delay between referral and treatment was incor-
porated in the calculation of the natural history data. This 
ZDVLPSRUWDQWLQRXUVWXG\DVZHQHHGHGWRÀQGWKH
FRQÀGHQFH LQWHUYDOV RI WKH ULVN RI ÀUVW KHPRUUKDJH IRU
the purpose of our comparison between surgery and no 
treatment of unruptured brain AVMs (ubAVMs). No 95% 
FRQÀGHQFHLQWHUYDOH[LVWHGLQWKHOLWHUDWXUH7KHUHIRUHZH
included the period between referral and surgery in the 
operated cases along with the unoperated cases to estab-
OLVKWKHFRQÀGHQFHLQWHUYDORIWKHULVNRIQH[WUXS-
ture. Because at 5 and 6 years the mean fell into the 95% 
FRQÀGHQFHLQWHUYDOUDQJHRIPHDQVUHSRUWHGLQWKHPHWD
analysis of Gross and Du,1 we believe our results for next 
KHPRUUKDJH UHÁHFW WKH H[SHULHQFH RI RWKHUV 7KH GHOD\
to treatment average differs considerably from the medi-
ans. The median time between referral and treatment was 
27 days (75th percentile 60 days), 38 days (75th percen-
tile 94 days), and 67 days (75th percentile 176 days) for 
Spetzler-Ponce Class A, B, and C lesions, respectively.2 
For ubAVMs this time delay is not unusual, as in our 
practice we encourage patients to take time to think about 
ZKDWZHKDYHUHFRPPHQGHGEHIRUHFRPLQJWRDÀQDOGH-
cision. This is especially so for the more complex brain 
$90V E$90V2I FRXUVH WKLV LQÁXHQFHV WKHPL[ RI
cases in the risk to rupture group (represented by more 
high-grade bAVMs). Having said this, there is little com-
pelling evidence that suggests that different grades of un-
ruptured bAVMs have different risk of rupture.
The question of generalizability of results is also im-
portant. We accept that in cohort studies the results are 
probably not generalizable. However, as Drs. Elhammady 
and Heros point out, and as Spetzler and Ponce have re-
viewed, there are a number of surgical series with very 
similar results to ours (although these series incorporate 
both ruptured and ubAVMs).2 We believe that the impor-
tant question of generalizability is of lesser importance 
than answering the question asked by ARUBA or by our 
study. There is a fundamental difference in these ques-
tions. ARUBA has asked, “IS” treatment of ubAVMs 
(by methods commonly recommended in units with a 
bias towards treatment modalities that are non-surgical) 
superior to no treatment (“best medical management”)? 
However, our question was, “CAN” surgical treatment 
of ubAVMs be superior to no treatment? This is not ad-
dressed by ARUBA in which 82% of patients in the treat-
ment arm were treated by means other than surgery. We 
believe that surgical treatment of ubAVMs can be supe-
rior to no treatment and that this conclusion in our study 
is realistic.
The argument regarding the type of center that should 
manage bAVMs is important. Centralization in academic 
or specialized units may have an advantage to ensure that 
there are enough cases of bAVMs to facilitate expertise 
in surgical treatment, benchmarking of outcomes, and 
PRGLÀFDWLRQRISUDFWLFHFRQWLQXLQJOHDUQLQJ
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